GeneOne specializes in nucleic-acid based treatments
and novel small-molecule therapeutics
Vaccines are a powerful tool to prevent infectious diseases.
GeneOne Life Science can rapidly develop its DNA vaccines.
GeneOne’s patented manufacturing technology, which has been developed over several years at VGXI, enables the rapid development and manufacture of large quantities of cGMP grade vaccine.
With the increasing occurrence of emerging new viral infectious diseases, GeneOne can leverage its nucleic acid-based vaccine platform to rapidly address new lethal diseases.
GLS-3000 Prevention of COVID-19 disease
gls-5100 Prevention of herpes zoster (shingles)
gls-5140 Prevention of severe fever with thrombocytopenia syndrome (SFTS)
gls-5300 Prevention of Middle East respiratory syndrome coronavirus (MERS-CoV) infection
GLS-5310 DNA Prevention of COVID-19 disease
gls-5700 Prevention of Zika virus infection
gls-6150 Prevention of hepatitis C
GLS-5100 Prevention of herpes zoster (shingles)
GLS-5140 Prevention of severe fever with thrombocytopenia syndrome (SFTS)
Prevention of Middle East respiratory syndrome coronavirus (MERS-CoV) infection
GLS-5700 Prevention of Zika virus infection
GLS-6100/GLS-6150 Prevention of hepatitis C
GLS-3000(mRNA) Prevention of COVID-19 disease
GLS-5310(DNA) Prevention of COVID-19 disease
GLS-5310(DNA) Prevention of coronavirus disease 2019 (COVID-19)
GLS-7000 HER2-targeted mAb Drug Resistant Breast Cancer
GLS-7100 Hemophilia A
GLS-8000 Prevention of Chronic Hepatitis B/Hepatitis B
GLS-8100 Rheumatoid Arthritis
GLS-1027 Acute ischemic nephritis
GLS-1027 COVID-19 Pneumonitis
GLS-1200 Chronic Rhinosinusitis
GLS-1200 COVID-19 Prophylaxis
GLS-1200 Influenza and Common cold viruses